artificial intelligence

Chinese companies now run seven of the eight IL-4Rα assets in Phase III — and the eighth is licensed to China too, with MG-K10’s latest Phase III data (94.3% EASI-75 at week 52) showing exactly why this comp set can’t be ignored.

The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target.

Daiichi Sankyo’s anti-TLR7 antibody just completed Phase 1b/2 — here’s how VibeOne sees the TLR7/8 landscape in lupus today.

The unmet need is real. Even with three approved biologics, roughly half of SLE patients hit a meaningful composite response at one year, and sustained remission is rare. TLR7 sits genetically upstream of the interferon axis that drives ~75% of disease — a clean, well-validated target.